Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, describes a study that discovered JAK2 alterations in patients with treatment-refractory triple-negative breast cancer.
Justin M. Balko, PharmD, PhD
Advertisement
Articles by Justin M. Balko, PharmD, PhD
Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, discusses research into clinically targetable genetic alterations in patients with triple-negative breast cancer.
Advertisement
Latest Updated Articles
Justin Balko on JAK2 Amplification in TNBCPublished: February 28th 2013 | Updated:
Justin Balko on the Diversity of Genetic Alterations in TNBCPublished: December 8th 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
2
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
3
Immune-Targeting Vaccine Shows Promise Intercepting Cancer in Patients With Lynch Syndrome
4
FDA Grants Orphan Drug Designation to Gotistobart in Squamous NSCLC
5